Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Viveta inhaled treprostinil: Preliminary Phase III data

In the double-blind, placebo-controlled, international Phase III TRIUMPH-1 trial in 235 patients with severe PAH, Viveta met the primary endpoint of

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE